Fig. 2

Canakinumab reduces the cellular motility of HK-2 cells treated with IL-1β. a Image representative of cells at time 0 and after 24 h of treatment with IL-1β or TGF-β with and without Canakinumab. b Histogram represents migration (in mm²) over 24 h of HK-2 cells before and after treatment with IL-1β or TGF-β in presence and absence of Canakinumab. Data are indicated as mean ± SD of three experiments. *p < 0.05, **p < 0.01 vs untreated control cells (CTR), ^##p < 0.01 vs untreated